Skip to main content

Table 3 Immunosuppressive treatment during the observation period

From: Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan

  Low BMI
(<  18.5)
Normal BMI (18.5–23.0) High BMI
(>  23)
P value
Baseline (n = 22) (n = 53) (n = 18)  
 Prednisolone (mg/day) 30 (30–30) 30 (30–40) 34 (40–50) < 0.001
  3rd month (n = 17) (n = 46) (n = 17)  
 Prednisolone (mg/day) 13 (10–15) 13 (10–15) 13 (10–15) 0.808
 Cumulative dose of prednisolone (g) 1.5 (1.5–1.6) 1.6 (1.4–1.8) 1.6 (1.4–1.9) 0.384
 Use of immunosuppressants [n (%)] 1 (5.9) 6 (13.0) 2 (12.5) 0.309
  6th month (n = 15) (n = 41) (n = 15)  
 Prednisolone (mg/day) 10 (8–10) 9 (8–10) 10 (7–10) 0.959
 Cumulative dose of prednisolone (g) 2.6 (2.5–3.1) 2.5 (2.1–3.0) 2.4 (2.0–3.2) 0.360
 Use of immunosuppressants [n (%)] 1 (6.7) 8 (19.5) 1 (6.7) 0.307
  1st year (n = 13) (n = 36) (n = 13)  
 Prednisolone (mg/day) 6 (5–8) 7 (5–8) 8 (5–8) 0.892
 Cumulative dose of prednisolone (g) 3.4 (3.1–4.1) 3.1 (2.7–43.9) 3.1 (2.7–3.8) 0.532
 Use of immunosuppressants [n (%)] 0 (0) 8 (22.2) 1 (7.7) 0.110
  2nd year (n = 11) (n = 26) (n = 8)  
 Prednisolone (mg/day) 5 (5–5) 5 (5–8) 5 (1–5) 0.267
 Cumulative dose of prednisolone (g) 5.1 (4.5–5.7) 5.1 (4.3–6.0) 5.0 (3.0–6.4) 0.906
 Use of immunosuppressants [n (%)] 1 (9.1) 11 (42.3) 1 (14.3) 0.081
  1. Median (interquartile range), categorical values are expressed as numbers (proportions)
  2. Abbreviations: BMI body mass index